Confo Therapeutics secures a EUR 1 million grant from VLAIO to develop ultra-long-acting antibody-based GPCR therapeutics for metabolic conditions.

Oct 08, 2025•3 days ago

Amount Raised

€1 Million

GhentBiotechnology

Investors

Flanders Innovation & Entrepreneurship (Vlaio)

Description

Confo Therapeutics announced today that it has secured a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The funding will be used to advance research and development of ultra-long-acting medicines targeting GPCRs. This grant reinforces Confo's leadership in GPCR drug discovery and development. The support will aid in the advancement of treatments for obesity and other metabolic disorders.

Company Information

Company

Confo Therapeutics

Location

Ghent, East Flanders, Belgium

About

Confo Therapeutics is the only GPCR company with a proprietary discovery engine that precisely targets desired GPCR conformations. This unique capability allows us to unlock a vast untapped potential for the discovery and development of breakthrough medicines. We are a clinical-stage company advancing a robust pipeline of large and small molecules focused on validated targets in endocrine and metabolic diseases, as well as addressing a broader array of critical unmet medical needs in collaboration with our partners. Our team of accomplished experts is dedicated to advancing our patent-protected technology, expanding our capabilities, and building out our pipeline to achieve the best possible therapeutic outcomes for patients.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns